Comparative Effects of GLP-1 Agonists, Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Diabetes Mellitus Outcomes

被引：1
作者：
Essop, Tasiyah [1 ]
Tran, Kyle [2 ]
Purdy, Amanda C. [3 ]
Daly, Shaun C. [3 ]
机构：
[1] State Univ New York Upstate Med Univ, Norton Coll Med, Dept Psychiat, 750 Adams St, Syracuse, NY 13210 USA
[2] Pacific Western Univ Hlth Sci, Coll Osteopath Med, 309 2nd St, Pomona, CA 91766 USA
[3] Univ Calif Irvine, Dept Surg, 3800 Chapman Ave, Orange, CA 92868 USA
来源：
CURRENT DIABETES REPORTS | 2024年 / 24卷 / 12期
关键词：
Diabetes remission; Bariatric surgery; GLP-1; agonist; Sleeve gastrectomy; Gastric bypass; LIFE-STYLE INTERVENTION; WEIGHT-LOSS; BARIATRIC SURGERY; RECEPTOR AGONIST; MORBID-OBESITY; DOUBLE-BLIND; TYPE-2; PLACEBO; EFFICACY; SAFETY;
D O I：
10.1007/s11892-024-01554-2
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of ReviewThe purpose of this review is to assess the effects of glucagon-like peptide-1 (GLP-1) agonists, sleeve gastrectomy (SG), and Roux-en-Y gastric bypass (RYGB) on type 2 diabetes mellitus (T2DM) remission. This review explores the efficacy, safety, and durability of these surgical and medical modalities of diabetes management.Recent FindingsStudies have shown that GLP-1 agonists achieve higher rates of T2DM remission compared to standard glucose-lowering medications and lifestyle changes. In addition to weight loss, bariatric surgery has been found to be highly effective in treating and inducing remission of T2DM. Studies suggest that post-surgical patients see enhanced glycemic control.SummaryBoth surgical interventions and GLP1 agonists are effective in achieving T2DM remission. Long-term follow-up and randomized controlled trials comparing bariatric surgery and GLP-1 agonists are necessary to evaluate their relative effectiveness in T2DM control. Further research is also needed to assess the combined effects of these treatment modalities.
引用
收藏
页码：273 / 289
页数：17
相关论文
共 26 条
[1]   Mechanisms of Weight Loss After Obesity Surgery [J].
Akalestou, Elina ;
Miras, Alexander D. ;
Rutter, Guy A. ;
le Roux, Carel W. .
ENDOCRINE REVIEWS, 2022, 43 (01) :19-34
[2]   PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes [J].
Aroda, Vanita R. ;
Rosenstock, Julio ;
Terauchi, Yasuo ;
Altuntas, Yuksel ;
Lalic, Nebojsa M. ;
Morales Villegas, Enrique C. ;
Jeppesen, Ole K. ;
Christiansen, Erik ;
Hertz, Christin L. ;
Haluzik, Martin .
DIABETES CARE, 2019, 42 (09) :1724-1732
[3]   Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes [J].
Brancati, F ;
Charleston, J ;
Cheskin, L ;
Clark, J ;
DiGregorio-Celnik, D ;
Friedman-Donze, L ;
Rubin, R ;
Stewart, K ;
Bray, GA ;
DeLee, DG ;
Boss, KR ;
Greenway, FL ;
Lovejoy, JC ;
Ryan, DH ;
Williamson, DA ;
West, DS ;
DiLillo, V ;
Raczynski, JM ;
Lewis, CE ;
Oberman, A ;
Thomas, S ;
Nathan, DM ;
Horton, ES ;
Turgeon, H ;
Jackson, SD ;
Blackburn, GL ;
Delahanty, L ;
Steiner, B ;
Cagliero, E ;
Mantzoros, C ;
Hill, JO ;
Phillipp, J ;
Hamman, RF ;
Schwartz, R ;
Regensteiner, J ;
Van Dorsten, B ;
McDermott, MT ;
Dills, DG ;
Foreyt, JP ;
Reeves, RS ;
Pownell, HJ ;
Balasubramanyam, A ;
Jones, PH ;
Saad, MF ;
Jinagouda, S ;
Chiu, K ;
Morales, L ;
Ghazarian, S ;
Navarrete, G ;
Iqbal, N .
CONTROLLED CLINICAL TRIALS, 2003, 24 (05) :610-628
[4]  
Bray GA, 1999, DIABETES CARE, V22, P623
[5]   Bariatric Surgery vs Lifestyle Intervention for Diabetes Treatment: 5-Year Outcomes From a Randomized Trial [J].
Courcoulas, Anita P. ;
Gallagher, James W. ;
Neiberg, Rebecca H. ;
Eagleton, Emily B. ;
DeLany, James P. ;
Lang, Wei ;
Punchai, Suriya ;
Gourash, William ;
Jakicic, John M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (03) :866-876
[6]   Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial [J].
Davies, Melanie ;
Faerch, Louise ;
Jeppesen, Ole K. ;
Pakseresht, Arash ;
Pedersen, Sue D. ;
Perreault, Leigh ;
Rosenstock, Julio ;
Shimomura, Iichiro ;
Viljoen, Adie ;
Wadden, Thomas A. ;
Lingvay, Ildiko .
LANCET, 2021, 397 (10278) :971-984
[7]   Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes A Randomized Clinical Trial [J].
Davies, Melanie ;
Pieber, Thomas R. ;
Hartoft-Nielsen, Marie-Louise ;
Hansen, Oluf K. H. ;
Jabbour, Serge ;
Rosenstock, Julio .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (15) :1460-1470
[8]   Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study [J].
Gadde, Kishore M. ;
Vetter, Marion L. ;
Iqbal, Nayyar ;
Hardy, Elise ;
Oehman, Peter .
DIABETES OBESITY & METABOLISM, 2017, 19 (07) :979-988
[9]   Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial [J].
Garvey, W. Timothy ;
Batterham, Rachel L. ;
Bhatta, Meena ;
Buscemi, Silvio ;
Christensen, Louise N. ;
Frias, Juan P. ;
Jodar, Esteban ;
Kandler, Kristian ;
Rigas, Georgia ;
Wadden, Thomas A. ;
Wharton, Sean .
NATURE MEDICINE, 2022, 28 (10) :2083-+
[10]   Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study [J].
Guja, Cristian ;
Frias, Juan P. ;
Somogyi, Aniko ;
Jabbour, Serge ;
Wang, Hui ;
Hardy, Elise ;
Rosenstock, Julio .
DIABETES OBESITY & METABOLISM, 2018, 20 (07) :1602-1614
123